Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
12.61
-0.88 (-6.52%)
At close: Sep 12, 2025, 4:00 PM EDT
12.83
+0.22 (1.74%)
After-hours: Sep 12, 2025, 7:53 PM EDT
Adaptive Biotechnologies Employees
Adaptive Biotechnologies had 619 employees as of December 31, 2024. The number of employees decreased by 90 or -12.69% compared to the previous year.
Employees
619
Change (1Y)
-90
Growth (1Y)
-12.69%
Revenue / Employee
$331,528
Profits / Employee
-$195,847
Market Cap
1.92B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 619 | -90 | -12.69% |
| Dec 31, 2023 | 709 | -81 | -10.25% |
| Dec 31, 2022 | 790 | -68 | -7.93% |
| Dec 31, 2021 | 858 | 236 | 37.94% |
| Dec 31, 2020 | 622 | 169 | 37.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADPT News
- 3 days ago - Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts - Seeking Alpha
- 5 weeks ago - Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR® - GlobeNewsWire
- 3 months ago - Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - GlobeNewsWire